低雄性和非酒精性脂肪肝疾病
Kasiani Papadimitriou1, Athanasios C Mousiolis2, Gesthimani Mintziori2
1Unit of Reproductive Endocrinology, First Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece. kasipapadim@gmail.com.
非酒精性脂肪性肝病 (NAFLD) 与男性和女性的催眠症有关. 了解这些联系对于有效治疗代谢功能障碍相关的脂肪性肝病 (MASLD) 和生殖健康至关重要.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 内分泌学 在内分泌学.
- 生殖医学 生殖医学
背景情况:
- 非酒精性脂肪性肝病 (NAFLD),现在被称为代谢功能障碍相关的脂肪性肝病 (MASLD),影响全球25-30%的成年人.
- 在男性和女性中,NAFLD与显著的生殖功能障碍有关.
- 肝脏在性类固醇代谢和性激素结合球蛋白 (SHBG) 生产中发挥着关键作用.
研究的目的:
- 阐明NAFLD/MASLD与男性和女性的阴道腺症之间的复杂关联.
- 探索将这些疾病联系在一起的病理生理机制.
- 讨论影响NAFLD/MASLD和阴性腺瘤的治疗策略.
主要方法:
- 关于NAFLD/MASLD和阴性腺体缺陷症的现有文献的综述.
- 分析连接肝脏疾病和性激素失衡的病理生理路径.
- 讨论当前和潜在的治疗干预措施.
主要成果:
- 在低腺患者中观察到NAFLD/MASLD的相当普遍性.
- 已经确定了NAFLD/MASLD和阴道腺症之间的多种病理生理联系.
- 一种疾病的治疗方法可能会影响另一种疾病,突出了相互联系.
结论:
- 在NAFLD/MASLD和阴性腺症之间的关系是复杂的和双向的.
- 了解共享途径对于综合治疗方法至关重要.
- 对同时解决这两种疾病的治疗选择进行进一步的研究是有必要的.
更多相关视频
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
08:35A Model of Experimental Steatosis In Vitro: Hepatocyte Cell Culture in Lipid Overload-Conditioned Medium
Published on: May 18, 2021
相关概念视频
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Obesity
Liver Physiology
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Hypoglycemia and Glucagon
